The Insulinoma Market is expected to reach USD 5,632.6 Million by 2030 at 6.9% CAGR during the forecast period 2022-2030.Insulinoma is a rare form of tumour of the beta cells of pancreas resulting in an excessive secretion of insulin, leading to hypoglycaemia. Most insulinomas are benign, however a few metastasize. The symptoms of insulinoma are hypoglycaemia and associated symptoms such as blurred vision, lethargy, diplopia, light headedness, and convulsions, unconsciousness, which can also be life-threatening. Severe hypoglycemia may result in seizures, coma, and permanent neurological damage. Symptoms such as palpitations, tachycardia, sweating, hunger, anxiety etc. are caused by catecholaminergic response to hypoglycaemia triggered by insulinomas.
Insulinomas occur in people between the ages of 40 and 60 and grow slowly. The exact causes of insulinoma are unknown, however, patients with multiple endocrine neplasia type 1 syndrome or von Hippel-Landau syndrome are more at risk. According to a cancer research, 10% of insulinomas are cancerous and approximately 10% of patients diagnosed with insulinoma have more than one tumour. Insulinomas affect between up to five people out of one million each year.
Surgery is the definitive treatment for insulinomas and 90% of patients are cured of the condition. However, surgery can cause diabetes if significant amount of the pancreas are removed. The development of minimal invasive surgery procedures such as laparoscopy has resulted in replacement of open pancreatomy which was once the gold standard of treatment. The market constraints are lack of awareness, misdiagnosis of the disease, risk of surgery, high cost of treatment etc.
March 2021: Zealand Pharma A/S, a biotechnology company that aims to bring innovation to the market through the development of innovative peptide therapeutics, announced today that the U.S. The Food and Drug Administration (FDA) has approved Zegalogue® (dasiglucagon) injection for the treatment of severe hypoglycemia in pediatric and adult patients with diabetes aged 6 years and older. This sanction will facilitate the ability of suitable children and adults with diabetes to manage sudden and severe hypoglycemia, which can rapidly escalate from a mild occurrence to an emergency. The clinical significance of the extent and consistency of the effect observed in the Phase 3 pivotal studies is underscored by the fact that minutes are crucial in severe hypoglycemia. Zegalogue resolved severe hypoglycemia after administration, with a median time to blood glucose recovery of 10 minutes in these clinical studies. A critical drop in blood glucose levels, which is predominantly associated with insulin therapy, is the cause of severe hypoglycemia, an acute, life-threatening condition that is one of the most feared complications of diabetes treatment. The prevalence of severe hypoglycemia among children under the age of 18 is particularly high, with 7 out of 100 children diagnosed with diabetes on insulin reporting such episodes within the past six months. Although patients have the capacity to monitor and adjust their blood glucose levels to maintain appropriate glycemic control, it is not always feasible to prevent a severe hypoglycemic event.
July 2021: Xeris Pharmaceuticals, Inc., a specialty pharmaceutical company that utilizes its innovative formulation technology platforms to create and market injectable and infusible drug formulations that are ready to use, announced that Gvoke HypoPen™ (glucagon injection) is now available by prescription in the United States for the treatment of severe hypoglycemia in adults and children with diabetes aged 2 years and older. The Gvoke HypoPen is the first premixed autoinjector that is ready to use and does not have a visible needle. It contains glucagon. Xeris is dedicated to guaranteeing that patients have access to this significant new development. Using the Gvoke® copay savings card, eligible commercially insured patients may pay as little as $0 for a two-pack of Gvoke HypoPen for a limited time. Additionally, Xeris provides a Patient Assistance Program to assist individuals who meet the eligibility criteria for Gvoke.
Research Methodology 
Intended Audience
The global insulinoma market has been segmented on the basis of type, diagnosis, treatment, and end user.
Based on type, the market has been segmented as benign, and metastasize.
Based on diagnosis, the market has been segmented as blood test, endoscopic ultrasound, Computed Tomography (CT), Magnetic Resonance Imaging (MRI) and others.
Based on treatment, the market has been segmented as surgery, drugs, radiofrequency ablation, chemotherapy and others.
Based on the end user, the market has been segmented as hospitals & clinics, academic and research, and others.
The Americas account for a significant market share owing to extensive use of medications and high expenditure on the health care. Additionally, the fastest uptake of new products and surgical procedures in the US drives the insulinoma market. Also, concentration of major healthcare companies in the developed countries of this region coupled with the larger insurance penetration is adding fuel to the market growth. Moreover, the US expend high on the healthcare, which accounts for 16% of GDP also cruises the sale of insulinoma treatment.
Europe is the second largest market in the world due to high income and strong healthcare penetration. European market growth is led by countries such as Germany and France. The UK is expected to be the fastest growing market over the assessment period.
Asia Pacific region is expected to grow rapidly and China and India are likely to lead this market due to fast growing healthcare sector and large unmet needs during the forecast period. South East Asian countries such as Vietnam, Thailand, and Malaysia are projected to contribute highly to the market growth.Gulf nations such as Saudi Arabia and the UAE are estimated to drive the Middle East & African market. Other Middle East nations to watch out for will be Kuwait, Jordan, Egypt and Iran.
The African region is expected to witness a moderate growth owing to poor economic and political conditions and poor healthcare development. However, Africa has the highest unmet needs in the world and cost-effective products will be the key to dominate the African market.
Some of key players profiled in the report are
| Report Attribute/Metric | Details |
| Market Size 2030 | USD 5632 Million |
| Compound Annual Growth Rate (CAGR) | 6.9% (2022-2030) |
| Base Year | 2022 |
| Market Forecast Period | 2022-2030 |
| Historical Data | 2018- 2021 |
| Market Forecast Units | Value (USD Million) |
| Report Coverage | Revenue Forecast, Market Competitive Landscape, Growth Factors, and Trends |
| Segments Covered | Types, Diagnosis, |
| Geographies Covered | North America, Europe, Asia Pacific, and the Rest of the World |
| Countries Covered | The US, Canada, German, France, UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil |
| Key Companies Profiled | Abcam plc, cironpharma, Pfizer Plc., Entax Medical, Olympus, Boston Scientific Corporation, Medtronic, Cook Medical, Cook Medical, Inc., |
| Key Market Opportunities | Insulinoma, a rare pancreatic neuroendocrine tumor, presents a significant market opportunity due to the rising incidence of the condition. |
| Key Market Dynamics | The prevalence of insulinoma is on the rise globally, attributed to improved diagnostic methods and awareness among healthcare professionals |
Insulinoma Market Highlights:
Leading companies partner with us for data-driven Insights.
Kindly complete the form below to receive a free sample of this Report
Assistant Manager He holds an experience of about 7+ years in market research and business consulting, working under the spectrum of life sciences and healthcare domains. rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. his expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc. in addition to the above, his other responsibility includes strategic tracking of high growth markets & advising clients on the potential areas of focus they could direct their business initiatives
Get in Touch
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)
